EFFECT filed Sep 11, 2026 at 00:15 ET
The SEC declared effective Spero Therapeutics' S-3 shelf registration (File No. 333-298641) on September 10, 2026, enabling the company to sell up to $300M in securities, including an immediate $100M at-the-market (ATM) common stock offering via Jefferies. This follows a prior S-3 filing 14 days ago and comes at a $68M market cap for a clinical-stage biotech with no approved products, making the ATM size (1.4x market cap) massively dilutive. The effectiveness removes the final regulatory barrier for a dilutive capital raise to fund preclinical development of SP001, with no near-term revenue prospects.